Raphael Pharmaceutical appoints new CFO amid departures

Q: What leadership changes did Raphael Pharmaceutical Inc. (RAPH) disclose?

Raphael Pharmaceutical Inc. reported that Ajay Kumar Dhadha resigned as Chairman and Director, and Guy Ofir resigned as Chief Financial Officer, General Counsel, and Director, with Uri Tadelis appointed as the new Chief Financial Officer.

Q: When did the chairman of Raphael Pharmaceutical Inc. (RAPH) resign?

The chairman, Ajay Kumar Dhadha, resigned as Chairman of the Board and Director effective June 30, 2026. His resignation is described as voluntary and not due to any disagreement with the company’s operations, policies, practices, financial reporting, management, or Board.

Q: When did Raphael Pharmaceutical Inc. (RAPH) CFO and General Counsel resign?

Raphael Pharmaceutical Inc. states that Guy Ofir voluntarily resigned as Chief Financial Officer, General Counsel, and Director effective July 16, 2026. The company notes that his resignation was not the result of any disagreement on operations, policies, practices, financial reporting, management, or Board matters.

Q: Who is the new Chief Financial Officer of Raphael Pharmaceutical Inc. (RAPH)?

Effective July 16, 2026, Raphael Pharmaceutical Inc. appointed Uri Tadelis as its Chief Financial Officer. His appointment follows the voluntary resignation of former CFO and General Counsel Guy Ofir from his roles with the company and its Board.

Q: Did the resignations at Raphael Pharmaceutical Inc. (RAPH) involve any disagreements?

The company states that the resignations of Ajay Kumar Dhadha and Guy Ofir were not the result of disagreements regarding its operations, policies, practices, financial reporting, management, or Board of Directors, characterizing the departures as voluntary.

Raphael Pharmaceutical Inc. reports several senior leadership changes.

Filing Impact

(High)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

Raphael Pharmaceutical Inc. reports several senior leadership changes. Ajay Kumar Dhadha voluntarily resigned as Chairman of the Board and Director, effective June 30, 2026. The company states his resignation was not due to any disagreement regarding operations, policies, practices, financial reporting, management, or the Board.

Guy Ofir voluntarily resigned as Chief Financial Officer, General Counsel, and Director, effective July 16, 2026, also described as not resulting from any such disagreement. Effective July 16, 2026, Uri Tadelis was appointed as the company’s Chief Financial Officer.

Positive

None.

Negative

Multiple senior departures: The company reports the resignation of its Chairman and its Chief Financial Officer/General Counsel, resulting in several board and executive role changes within a short period.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Key Terms

Emerging growth company, Chief Financial Officer, Board of Directors, General Counsel

4 terms

Emerging growth company regulatory

"Emerging growth company"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

Chief Financial Officer financial

"appointed Mr. Uri Tadelis as its Chief Financial Officer"

A Chief Financial Officer (CFO) is the person in charge of a company's money and financial planning. They decide how to spend, save, and invest funds to help the company grow and stay stable. Their role is important because good financial decisions keep the company healthy and successful.

Board of Directors regulatory

"resigned from his positions as Chairman of the Board of Directors"

The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.

General Counsel regulatory

"resigned from his positions as Chief Financial Officer, General Counsel"

A general counsel is the chief lawyer of an organization, responsible for overseeing all legal matters and ensuring the company complies with laws and regulations. Think of them as the organization's legal advisor or navigator, helping to prevent legal problems before they happen. Their role matters to investors because they help protect the company from legal risks that could impact its success and value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What leadership changes did Raphael Pharmaceutical Inc. (RAPH) disclose?

Raphael Pharmaceutical Inc. reported that Ajay Kumar Dhadha resigned as Chairman and Director, and Guy Ofir resigned as Chief Financial Officer, General Counsel, and Director, with Uri Tadelis appointed as the new Chief Financial Officer.

When did the chairman of Raphael Pharmaceutical Inc. (RAPH) resign?

The chairman, Ajay Kumar Dhadha, resigned as Chairman of the Board and Director effective June 30, 2026. His resignation is described as voluntary and not due to any disagreement with the company’s operations, policies, practices, financial reporting, management, or Board.

When did Raphael Pharmaceutical Inc. (RAPH) CFO and General Counsel resign?

Raphael Pharmaceutical Inc. states that Guy Ofir voluntarily resigned as Chief Financial Officer, General Counsel, and Director effective July 16, 2026. The company notes that his resignation was not the result of any disagreement on operations, policies, practices, financial reporting, management, or Board matters.

Who is the new Chief Financial Officer of Raphael Pharmaceutical Inc. (RAPH)?

Effective July 16, 2026, Raphael Pharmaceutical Inc. appointed Uri Tadelis as its Chief Financial Officer. His appointment follows the voluntary resignation of former CFO and General Counsel Guy Ofir from his roles with the company and its Board.

Did the resignations at Raphael Pharmaceutical Inc. (RAPH) involve any disagreements?

The company states that the resignations of Ajay Kumar Dhadha and Guy Ofir were not the result of disagreements regarding its operations, policies, practices, financial reporting, management, or Board of Directors, characterizing the departures as voluntary.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 07/17/2026 - 09:20 AM EDT

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of report (Date of earliest event reported): July 16, 2026 (July 16, 2026)

RAPHAEL PHARMACEUTICAL INC.

(Exact Name of Registrant as Specified in Its Charter)

Nevada		000-53002		26-0204284
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

4 Lui Paster

Tel Aviv-Jaffa, Israel

6803605

(Address of Principal Executive Offices)

(Zip Code)

+972 52 775 5072

(Registrant’s telephone number, including area code)

Not applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
N/A		N/A		N/A

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensation Arrangements of Certain Officers.

Mr. Ajay Kumar Dhadha voluntarily resigned from his positions as Chairman of the Board of Directors and Director of the Company, effective June 30, 2026. His resignation was not the result of any disagreement with the Company regarding its operations, policies, practices, financial reporting, management, or Board of Directors.

Mr. Guy Ofir voluntarily resigned from his positions as Chief Financial Officer, General Counsel, and Director of the Company, effective July 16, 2026. His resignation was not the result of any disagreement with the Company regarding its operations, policies, practices, financial reporting, management, or Board of Directors.

Effective July 16, 2026, the Company appointed Mr. Uri Tadelis as its Chief Financial Officer.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	RAPHAEL PHARMACEUTICAL INC.

	By:	/s/ Shlomo Pilo
	Name:	Shlomo Pilo
	Title:	Chief Executive Officer

Date: July 16, 2026

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

3 documents